As a result, we found that the 1-year cumulative recurrence-free survival in HCC patients with LOH on ZDHHC2 was significantly lower than that with heterozygosity retention (P = 0.022, Figure 2). The gene discussed is ZDHHC2; the disease is hepatocellular carcinoma.